The global Radioligand Therapy (RLT) Market is projected to grow from USD 3.15 billion in 2025 to USD 10.91 billion by 2035, registering a CAGR of 13.2% during the forecast period, according to a market research report published by MarketsandMarkets™.
The market is witnessing strong momentum due to the rising prevalence of cancer, increasing adoption of precision oncology, and a robust pipeline of radioligand therapeutics. Advances in targeted radiopharmaceuticals, growing utilization of PSMA and SSTR imaging for patient selection and expanding regulatory approvals are further accelerating market growth.
Radioligand therapy has emerged as a transformative treatment modality that delivers radiation directly to cancer cells while minimizing damage to surrounding healthy tissues. Continued investments in next-generation ligand design, isotope production capabilities, and strategic collaborations among pharmaceutical and biotechnology companies are expected to drive future innovation across the market.
Access key market insights and highlights from the report
brochure:
Download
Report Brochure
Prostate Cancer Segment Leads Market Growth
Based on indication, the prostate cancer segment accounted for the largest share of the market and is expected to register the highest growth rate, with a projected CAGR of 13.7% during the forecast period.
The increasing global burden of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), has created substantial demand for targeted treatment options. Radioligand therapies such as Lutetium-177 vipivotide tetraxetan (Pluvicto) and emerging PSMA-targeted radiopharmaceuticals are demonstrating significant improvements in patient outcomes, including extended survival and enhanced quality of life.
PSMA Segment Expected to Witness Fastest Growth
By target, the Prostate-Specific Membrane Antigen (PSMA) segment is expected to grow at the fastest rate during the forecast period. The growing adoption of PSMA-targeted imaging and therapy approaches is enabling more accurate patient selection and improved therapeutic effectiveness, supporting wider clinical adoption.
Lutetium-177 Vipivotide Tetraxetan Segment Shows Strong Potential
By product, the Lutetium-177 vipivotide tetraxetan (Pluvicto) segment is anticipated to register significant growth during the forecast period. Increasing clinical acceptance, expanding indications, and favorable treatment outcomes continue to strengthen demand for Lu-177-based radioligand therapies worldwide.
North America Maintains Market Leadership
North America accounted for the largest share of the global radioligand therapy market in 2024. The region benefits from advanced healthcare infrastructure, early adoption of innovative oncology treatments, strong regulatory support, and the presence of leading pharmaceutical and biotechnology companies.
The region's extensive network of academic medical centers and comprehensive cancer treatment facilities continues to drive clinical research, commercialization, and patient access to cutting-edge radioligand therapies.
Asia Pacific Emerges as Fastest-Growing Regional Market
The Asia Pacific market is projected to register the highest growth during the forecast period. Rising investments in nuclear medicine infrastructure, increasing availability of PET/CT and SPECT imaging systems, expanding theranostics programs, and growing cancer incidence are supporting regional market expansion.
Countries including China, Japan, South Korea, India, and Australia are strengthening isotope production capabilities and radiopharmaceutical manufacturing infrastructure to meet growing demand for radioligand therapies.
Industry Focus Shifts Toward Next-Generation Radioligand Therapies
The market is increasingly moving toward advanced alpha-emitting therapies, including Actinium-225 and Lead-212, which offer highly localized radiation delivery with the potential for improved efficacy and reduced toxicity compared with traditional beta-emitting therapies.
Manufacturers are also investing in innovative ligand technologies designed to improve tumor targeting, increase therapeutic stability, and enable combination treatment strategies with immuno-oncology therapies.
Key Market Participants
Major companies operating in the global radioligand therapy market include Novartis, Bayer, Curium, Eli Lilly & Co., AstraZeneca, Progenics Pharmaceuticals, Ariceum Therapeutics, Telix Pharmaceuticals, ITM Isotope Technologies Munich SE, Convergent Radiopharma, Orano SA, Actinium Pharmaceuticals, Perspective Therapeutics, and Clarity Pharmaceuticals.
According to the report, Novartis continues to maintain a strong position in the market through its approved radioligand therapy products and global theranostics infrastructure, while companies such as ITM Isotope Technologies are expanding isotope production capabilities to address growing industry demand.
The report highlights that increasing approvals, manufacturing scale-up initiatives, strategic partnerships, and continued innovation across the radiopharmaceutical ecosystem will play a critical role in shaping the future of the global radioligand therapy market.
Connect with the research team for customized insights,
regional analysis, enterprise-specific requirements, or analyst consultation:
Request
Inquiry / Speak to Analyst
Explore Related Radioligand Therapy (RLT) Market Reports
Precision Diagnostics & Medicine Market
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
